Navigation Links
Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
Date:12/13/2007

Summary: Genmab has Announced Details of a Planned Phase II Study of

Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 receptor. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"Multiple sclerosis is a debilitating disease for which there are currently few treatments," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We hope our fully human antibody, ofatumumab, may offer another potential treatment option for patients suffering from this incapacitating disease."

About the trial

The double blind randomized trial will consist of two parts. Part A will include approximately 36 patients in one of three increasing dose cohorts (100 mg, 300 mg or 700 mg of ofatumumab) randomized to receive ofatumumab or placebo. An independent data monitoring committee (IDMC) will evaluate the safety of each sequential cohort prior to progression to the next cohort. When all patients in Part A have had their week 4 MRI scan, the IDMC will evaluate the data before Part B of the study begins.

Part B will consist of a 48 week treatment period of approximately 288 patients. Patients will be randomized to treatment with 100 mg, 300 mg, or 700 mg of ofatu
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... TRIANGLE PARK, N.C. , May 29, 2015 ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Jefferies 2015 Global Healthcare Conference ... The presentation and the immediately following Q&A session will take ... Time, and can be accessed via a live webcast on ...
(Date:5/28/2015)... 28, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... and Companies" to their offering. ... This report deals with therapeutic drug monitoring, ... patient care by monitoring drug levels in ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ... new report "Cell Therapy - Technologies, Markets ... This report describes and evaluates cell therapy technologies ... an important role in the practice of medicine. ... fashioned bone marrow transplants. Role of cells in ...
(Date:5/28/2015)... 28, 2015 DryLet, LLC a ... applications such as animal waste reduction, bioremediation, wastewater ... in wastewater treatment plants and restaurant kitchen settings, ... Pork Expo, June 3-5 in Des Moines, Iowa. ... a Wall Street Journal article because of its ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2
... . - Every surgical operation requires proper wound closure ... a Madison start-up business has received a $100,000 federal ... , Nerites Corp ., which develops tissue repair products ... a $100,000 Small Business Innovation Research grant. ...
... experience high rates of failure. As a result, many ... partner. The result stifles innovation, growth, and a company's ... shedding the flawed processes of yesterday, and introducing methods ... promising incremental delivery of functional software. , , Evidence ...
... Madison, Wis. - With the goal of transforming ... of Wisconsin-Madison has approved a new research entity ... ,The institute is a collaboration of the four UW-Madison ... and Veterinary Medicine. It will partner with the Marshfield ...
Cached Biology Technology:Agile Revolution: A new era of software delivery 2Agile Revolution: A new era of software delivery 3Agile Revolution: A new era of software delivery 4
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... the most commonly cultivated cacao plant in the world ... this week. Researchers have utilised high quality DNA sequences to ... markers that can lead to higher yielding cocoa plants that still ... the cacao tree ( Theobroma cacao L. ...
... species, according to a new study led by Woods ... published in the journal PLOS ONE . Because ... may have far-reaching effects on the ocean environment and ... the center of the ocean ecosystemnearly all animals are ...
... insecurity increases the risk of death among injection drug ... life-prolonging antiretroviral therapy (ART), according to a new study ... the peer-reviewed science journal, PLoS One , examines ... among injection drug users. Food insecurity is defined by ...
Cached Biology News:Genome hints at markers for higher-producing, better-tasting chocolate 2Acidifying oceans could spell trouble for squid 2Acidifying oceans could spell trouble for squid 3Food insecurity linked to HIV-treated drug users' deaths 2
... The 1-D PAGE Cleavable ... for Targeted Protein ID ... PolyAcrylamide Gel Electrophoresis (PAGE), ... and cleavable-linker technology to ...
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Qa-1 (L-12)...
... , Coated Capture Antibody: 12 x 8-well strips, ... mL of 2X concentrate , Beta Amyloid ... , Lyophilized Standard Diluent: 3 mL , Primary ... Antibody-HRP: 30 microL of concentrate , OPD Substrate: ...
Biology Products: